Logan Steele
Fibrodysplasia ossificans progressiva (FOP) is a rare disease that causes muscles and connective tissues to ossify into bone, resulting in severe disability and even death. Affecting about one in two million people, FOP is characterized by the gradual replacement of muscles, ligaments, and tendons with bone, leading to locked joints, distorted posture, and restricted movement. The disease is caused by a mutation in the ACVR1 gene, which results in the overactivation of a cell surface protein that stimulates bone growth. While there is currently no cure for FOP, researchers have made promising breakthroughs with potential treatments, offering hope to those affected by this devastating condition.
| Characteristics | Values |
|---|---|
| Name of the disease | Fibrodysplasia Ossificans Progressiva (FOP) |
| Occurrence | Rare, occurs in about one in two million people |
| Cause | Mutation in the gene ACVR1 (also known as activin-like kinase 2 or ALK2) |
| Symptoms | Joints become frozen in place, jaw motion is impeded, rib cage is fixed, difficulty in breathing, progressive loss of mobility, malnutrition, inability to speak |
| Diagnosis | Radiographs, radiology |
| Treatment | Anti-inflammatory drugs, monoclonal antibody, Sohonos (palovarotene) |
Explore related products
What You'll Learn
Fibrodysplasia ossificans progressiva (FOP)
The symptoms of FOP typically become noticeable in early childhood, starting with the neck and shoulders and progressing down the body to the limbs. Individuals with FOP often experience muscle swelling and inflammation (myositis) followed by rapid ossification in the affected area. This can be triggered by trauma to the muscles, such as a fall or invasive medical procedures, or by viral illnesses such as influenza.
FOP is caused by a mutation in the ACVR1 gene, which encodes a bone morphogenic protein (BMP) receptor. This mutation results in the overactivation of the receptor, leading to the transformation of connective tissue and muscle tissue into bone. The typical mutation, R202H, affects the binding of the inhibitor FKBP1A to the activation GS-loop, preventing the effective deactivation of the ACVR1 protein.
The diagnosis of FOP can be made through radiographs, and early diagnosis is important to avoid unnecessary invasive investigations like biopsies, which can exacerbate bone growth. While there is currently no cure for FOP, treatments such as anti-inflammatory drugs can help manage inflammation and flare-ups. A potential therapy, using a monoclonal antibody, has shown promising results in mice models, but its effectiveness in humans is yet to be determined.
FOP has earned the nickname "stone man disease" due to the progressive ossification that leaves sufferers immobilised. The disorder can lead to severe disability, with individuals experiencing difficulty in speaking, eating, and breathing. The median age of survival for those with FOP is 40 years, but this can be decreased by factors such as delayed diagnosis, trauma, and infections.
Muscle Power: Why We're Attracted to Strength
You may want to see also
Explore related products
$27.95
Gene mutation
Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disorder that causes muscle and connective tissue to gradually transform into bone. This process, known as heterotopic ossification, results in the formation of bone outside the skeleton, limiting movement and causing joint fusion. The disease typically manifests at birth, with the baby exhibiting a bent big toe. By early childhood, connective tissues, muscles, ligaments, and tendons begin to ossify, leading to progressive loss of mobility.
At the genetic level, FOP is caused by a mutation in the ACVR1 gene, which encodes a bone morphogenetic protein (BMP) receptor. This receptor is crucial for bone and muscle growth and development. The most common mutation, R202H, affects the binding of the inhibitor FKBP1A to the ACVR1 gene, resulting in its constant activation. This leads to overgrowth of bone and cartilage and the fusion of joints. Most cases of FOP arise from new mutations, with no prior family history, while a small number of cases involve inheritance from an affected parent.
Progressive osseous heteroplasia (POH) is another rare inherited disorder characterised by heterotopic ossification. Unlike FOP, POH initially presents as bone growth on the skin's surface, eventually spreading to deeper levels and affecting various tissues, including muscle, fat, and connective tissues. POH is caused by a variant in the GNAS gene, resulting in abnormal bone development and restricted joint movement.
In addition to FOP and POH, other genetic disorders can also impact both bone and muscle health. For example, Duchenne and Becker muscular dystrophies are caused by mutations in the DMD gene, leading to muscle abnormalities and impaired bone health. Hypophosphatemic rickets is another disorder characterised by muscle abnormalities and soft bones due to mutations in the PHEX, FGF23, and DMP1 genes.
The study of pleiotropy, or the influence of genes on multiple traits, has provided valuable insights into the complex interplay between bone and muscle health. Researchers have identified genes with potential pleiotropic effects on both bone and muscle, such as MEF2C and SREBF1. These findings may lead to the development of novel treatment strategies for diseases affecting bone and muscle, such as osteoporosis and sarcopenia.
Aiding Muscle Recovery: Effective Strategies for Optimal Results
You may want to see also
Explore related products
Muscle and connective tissue ossification
The process of muscle and connective tissue ossification in FOP typically begins in early childhood, with the connective tissues, muscles, ligaments, and tendons gradually ossifying into skeletal bone. This process can occur spontaneously or be triggered by trauma, even from a minor event like a stretched tendon or muscle. The bone that forms is independent of the normal skeleton but can fuse with it, leading to locked joints and distorted posture and movement. The diaphragm, tongue, and extra-ocular muscles are typically spared in FOP, but other joints such as the elbows, ankles, and jaw may become frozen in place, making eating, breathing, and moving difficult.
Another form of muscle and connective tissue ossification is heterotopic ossification (HO), which can occur after an injury, surgery, or for no apparent reason. In HO, bone tissue develops in soft tissues, forming painful bony lumps that can restrict movement, particularly if they are near a joint. While HO can often be treated with non-surgical methods such as NSAIDs and physical therapy, genetic forms of HO are rarer and more severe.
The treatment of muscle and connective tissue ossification depends on the underlying cause. While there is currently no cure for FOP, a promising breakthrough is the approved treatment Sohonos (palovarotene). Additionally, researchers have identified a potential therapy in the form of a monoclonal antibody that prevented the growth of new bone in mice with FOP. For HO, treatment options include medications such as corticosteroids, physical therapy, and, in severe cases, surgery to remove the heterotopic bone.
The Unique Structure of Cardiac Muscle Cells
You may want to see also
Explore related products
Bone morphogenetic protein (BMP)
Bone morphogenetic proteins (BMPs) are a highly conserved and diverse family of multifunctional cytokines and growth factors. They are morphogens that play a crucial role in controlling the development and formation of bones, cartilage, and other tissues. BMPs are involved in the patterning of the neural tube during early embryonic development and have been implicated in the formation and patterning of the central nervous system (CNS). They are expressed in specific cells and regulate cell fate, proliferation, survival, and differentiation in response to injury or other stimuli.
BMPs belong to the transforming growth factor beta (TGF-β) superfamily and interact with specific receptors on the cell surface, known as bone morphogenetic protein receptors (BMPRs). The binding of BMPs to these receptors initiates a signalling cascade that is essential for inducing bone formation during development and maintaining tissue homeostasis. This signalling pathway also involves members of the SMAD family of proteins, and it has important roles in embryonic development, skeletal formation, and the development of the heart and central nervous system.
The biological basis of bone morphogenesis was demonstrated by Marshall R. Urist in 1965. Urist discovered that demineralized, lyophilized segments of bone induced new bone formation when implanted in muscle pouches in rabbits. This led to the proposal of the term "Bone Morphogenetic Protein" in the scientific literature. Subsequent studies by Hari Reddi and colleagues further unravelled the sequence of events involved in bone matrix-induced bone morphogenesis, leading to the isolation and purification of BMPs.
BMPs have potential therapeutic applications due to their broad biological functionality. Recombinant human BMP2 and BMP7 have been approved by the US Food and Drug Administration (FDA) for treating open tibial shaft fractures and long bone non-unions, respectively. BMPs have also shown efficacy in restoring various types of bone defects in humans. However, the routine use of BMPs in certain procedures, such as anterior cervical spine fusion, is not recommended due to reports of life-threatening complications caused by soft tissue swelling.
In rare cases, mutations in the ACVR1 gene, which encodes a BMP receptor, can lead to a disease called fibrodysplasia ossificans progressiva (FOP). This disease results in the abnormal activation of ACVR1, causing the transformation of connective tissue and muscle tissue into bone. The typical mutation, R202H, affects the binding of the inhibitor FKBP1A, leading to overgrowth of bone and cartilage and the fusion of joints. While there is no cure for FOP, promising treatments, such as monoclonal antibodies, are being investigated to prevent the buildup of bone associated with this condition.
Groin Muscles: Supporting Your Body's Core Stability
You may want to see also
Explore related products
$26.49
Treatment and cure
Fibrodysplasia Ossificans Progressiva (FOP), also called Münchmeyer disease or myositis ossificans progressiva, is an extremely rare connective tissue disease in which muscle, tendons, and ligaments turn into bone tissue. It is caused by a mutation of the gene ACVR1, which affects the body's repair mechanism, causing fibrous tissue to become ossified. There is currently no cure for FOP, but there are some treatments that can help manage the condition.
One treatment option for FOP is Sohonos (palovarotene), which has been approved for use in treating the disease. This medication targets the mutated ACVR1 gene, which causes heterotopic ossification by responding aberrantly to activin A. LNA gapmers have also been shown to effectively reduce the expression of the pathogenic ACVR1R206H transcript, selectively suppressing osteogenic differentiation associated with FOP. This approach offers potential for therapeutic application in FOP and other similar disorders.
Another potential treatment for FOP is the use of monoclonal antibodies. In a study, mice with FOP were given a monoclonal antibody treatment, and it was found that this prevented the growth of new bone. Additionally, saracatinib, a potent heterotopic ossification inhibitor, was in phase III clinical trials as of 2021 and may hold promise as a treatment for FOP.
It is important to avoid activities that increase the risk of falling or soft tissue injury, as even minor trauma can trigger heterotopic ossification in people with FOP. Intramuscular injections, including immunizations, should also be avoided for the same reason. Anti-inflammatory drugs can be used to suppress inflammation and flare-ups caused by muscle damage.
While not a cure, these treatments can help manage the symptoms and progression of FOP. It is hoped that further research and understanding of the disease will lead to the development of more effective treatments and, eventually, a cure for this rare and disabling disorder.
Building Muscle: The Best Exercises to Bulk Up
You may want to see also
Frequently asked questions
A mutation in the gene ACVR1 causes abnormal activation of ACVR1, leading to the transformation of connective tissue and muscle tissue into a secondary skeleton. This condition is called fibrodysplasia ossificans progressiva (FOP).
FOP causes bones to form outside the skeleton, limiting movement. Joints may become frozen in place, and the rib cage may be affected, making eating or breathing difficult. People with FOP may also experience malnutrition due to their eating problems.
FOP is a rare disease, occurring in about one in two million people.
There is currently no cure for FOP, but there are treatments available to manage the condition, such as anti-inflammatory drugs to suppress inflammation and monoclonal antibodies, which have been shown to stop the growth of new bone in mice.
